Infliximab in rheumatic diseases
| dc.contributor.author | Janse van Rensburg, Dina Christina | |
| dc.date.accessioned | 2014-07-04T06:40:12Z | |
| dc.date.available | 2014-07-04T06:40:12Z | |
| dc.date.issued | 2013-06 | |
| dc.description | In this article no comparison with regards to long-term efficacy and safety was made to other biologic drugs. | en_US |
| dc.description.abstract | Infliximab (REVELLEX®) is a chimeric IgG1κ monoclonal antibody against tumor necrosis factor-α (TNF-α). Infliximab is indicated, for the treatment of rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), Crohn’s disease (CD, ulcerative colitis (UC) and skin psoriasis. The first aim of this article is to revisit the indications for the use of Infliximab in RA, AS and PsA. The second aim is to get an update on the newest insights on the safety and efficacy of the drug. | en_US |
| dc.description.librarian | am2014 | en_US |
| dc.description.uri | http://www.media24.com/en/magazines/business-magazines/sa-rheumatology-journal.html | en_US |
| dc.identifier.citation | Janse van Rensburg, DC 2013, 'Infliximab in rheumatic diseases', South African Rheumatology Journal, vol. 5, no. 2, pp. 21-24. | en_US |
| dc.identifier.uri | http://hdl.handle.net/2263/40539 | |
| dc.language.iso | en | en_US |
| dc.publisher | Media 24 | en_US |
| dc.rights | Media 24 | en_US |
| dc.subject | Infliximab | en_US |
| dc.subject | Tumor | en_US |
| dc.subject | Treatment | en_US |
| dc.subject | Rheumatoid arthritis | en_US |
| dc.title | Infliximab in rheumatic diseases | en_US |
| dc.type | Article | en_US |